Humana (HUM) is back in focus after recent analyst updates pointed to the possibility of upcoming quarterly earnings beating consensus estimates, with a positive Earnings ESP and strong buy ratings drawing investor attention.

Humana's share price has had a strong run recently, with a 30 day share price return of 10.22% and a 90 day share price return of 84.97%, while the 1 year total shareholder return of 70.10% contrasts with weaker 3 and 5 year total shareholder returns.

If Humana's recent move has you thinking about where else momentum and earnings stories might emerge in healthcare, it could be a good time to scan 41 healthcare AI stocks.

Humana now trades above the average analyst price target, yet internal fair value estimates suggest a wide potential discount. After such a sharp move, where does a reasonable valuation actually sit within that range?

Most Popular Narrative: 86.8% Overvalued

Humana's last close at $397.60 sits well above the fair value of $212.87 implied by the most followed narrative. This applies a 6.978% discount rate and points to a stretched price against its own cash flow assumptions.

Humana’s current pressures underscore that reality. As Medicare Advantage continues to expand, the companies that thrive will likely be those that treat compliance not as a checkbox, but as an operational framework embedded into every layer of their billing and clinical review systems.

Curious what sits behind that gap between price and fair value? The narrative leans heavily on specific revenue trajectories, profit margins and future earnings multiples that paint a very different long term picture for Humana.

Result: Fair Value of $212.87 (OVERVALUED)

However, if Humana strengthens its compliance systems, or if regulators ease pressure on Medicare Advantage documentation, that could narrow the gap this narrative highlights.

Another View on Humana’s Valuation

The most followed Humana narrative pins fair value at $212.87 and flags the stock as 86.8% overvalued, but the SWS DCF model paints a very different picture. On that view, Humana at $397.60 trades well below an estimated future cash flow value of $1,051.70, which implies a wide margin to the upside instead of downside risk. When two methods disagree this sharply, which set of assumptions would you trust more: the cash flows or the narrative inputs?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Humana for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the divergent views on Humana's value and outlook, it may be useful to review the underlying data now and compare your own thesis with the company's 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Humana?

If Humana has sparked fresh questions about your portfolio, you may want to use this moment to line up your next ideas before the market moves without you.

• Spot potential outliers early by scanning screener containing 20 high quality undiscovered gems that may not yet be crowded with attention.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (49 results) to see which businesses pair resilience with fundamentals.
• Dial back portfolio stress by focusing on the 82 resilient stocks with low risk scores so that higher conviction does not rely on higher volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.